HOUSE 2815117th CongressReferred to the Subcommittee on Health.
BIOSIM Act
- Last Action
- 4/23/2021
Actions
- 2021-04-23Referred to the Subcommittee on Health.
- 2021-04-22Referred to the Subcommittee on Social Security.
- 2021-04-22Referred to the Subcommittee on Health.
- 2021-04-22Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2021-04-22Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2021-04-22Introduced in House
- 2021-04-22Introduced in House
CRS Summary
As of 2021-04-22 (00)
Bolstering Innovative Options to Save Immediately on Medicines Act or the BIOSIM Act
This bill increases Medicare payments for biosimilars for five years. The bill applies to biosimilars for which the average sales price or wholesale acquisition cost is less than that of the reference biological product, as specified.
Cosponsors (4)
- Adam Kinzinger (R-IL)
- Mikie Sherrill (D-NJ)
- G. K. Butterfield (D-NC)
- Kim Schrier (D-WA)
Subjects
- Health care costs and insurance
- Medicare
- Prescription drugs
- Product development and innovation
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.